HealthyDirect · GrowthFit for a long SIP
JM Mid Cap Fund
JM Financial Mutual FundEquity Schemes - Mid Cap Fund3.9 years
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. There is no assurance that the investment objective of the Scheme will be realized.
- NAV
- 20.7892
- 30 Oct 2026
- 1Y
- -0.1%
- Trailing CAGR
- Upside capture
- +107%
- Vs NIFTY MIDCAP 150 TRI
- Downside capture
- +91%
- Lower is better
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Buy checklist
History depth
Watch
3.9 years - usable, still building a track record.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.95% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -22.5%. Ask whether you can hold through a similar fall.
Vs category
Watch
54% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Watch
Deepak Gupta · 1.6 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 28.2% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 23%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y-0.1%
- 3Y+17.3%
- 5Yn/a
- 10Yn/a
- SI+20.4%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+2.2%
- 3Y+6.8%
- 5Yn/a
- 10Yn/a
- Since inception
- +20.4%
- Calendar-day CAGR
- Excess 1Y
- +0.4%
- Category median, same plan and option
- 3Y win rate
- +54%
- Windows beating the median
- 3Y percentile
- 56
- Vs comparable share classes
- SIP 3Y XIRR
- +6.8%
- Simulated monthly SIP
- Worst rolling 3Y
- +15.6%
- 231 daily-ending windows
- Median rolling 3Y
- +24.0%
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
Official benchmark
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
- 1Y excess
- +4.3%
- Fund minus TRI
- 3Y excess
- +3.5%
- Fund minus TRI
- Upside capture
- +107%
- Benchmark-up months
- Downside capture
- +91%
- Lower is better
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -22.5%
- Worst peak-to-trough
- Current
- -10.1%
- Below last peak
- Current spell
- 60 days
- Days below latest peak
- Time below peak
- +82%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 14 days
- 57 recovered episodes
- Longest recovery
- 472 days
- Trough to prior peak
24 Sept 2024 – 15 Jun 2026
Trough 28 Feb 2025 · recovered in 472 days
-22.5%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-13.2%
3 Jun 2024 – 11 Jun 2024
Trough 4 Jun 2024 · recovered in 7 days
-7.8%
7 Feb 2024 – 2 Apr 2024
Trough 13 Mar 2024 · recovered in 20 days
-7.4%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
56
Vs category
53
Consistency
52
Risk-adjusted
68
Drawdown
44
Mean
54
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 74 holdings · top 10 are 28.2%.
- Top 5
- 15.3%
- Top 10
- 28.2%
- Largest holding
- 3.6%
- Effective holdings
- 55.0
One 97 Communications Ltd
Industrials
3.6%
Avalon Technologies Ltd.
Industrials
3.1%
Mankind Pharma Ltd.
Healthcare
2.9%
Godfrey Phillips India Ltd
Consumer Staples
2.9%
IDFC First Bank Ltd
Financial
2.8%
What changed
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
19 Oct 2026
DECISION
Status moved from HEALTHY to MONITOR.
19 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
18 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
17 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
15 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
11 Sept 2026
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
WhiteOak Capital Mid Cap Fund
WhiteOak Capital Mutual Fund
- 1Y
- +3.6%
- 3Y
- +20.4%
- Vol
- 14.8%
- Max DD
- -19.3%
- Sharpe
- 0.98
- 3Y win
- +100%
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
- Lower TER
- Higher trailing returns
Helios Mid Cap Fund
Helios Mutual Fund
- 1Y
- +0.9%
- 3Y
- n/a
- Vol
- 16.5%
- Max DD
- -16.7%
- Sharpe
- 0.76
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
- Higher win rate vs category
- Lower TER
Caveat: Lower trailing returns
Kotak Mid Cap Fund
Kotak Mahindra Mutual Fund
- 1Y
- -4.5%
- 3Y
- +15.0%
- Vol
- 15.4%
- Max DD
- -36.0%
- Sharpe
- 0.85
- 3Y win
- +68%
- Lower volatility
- Higher win rate vs category
- Lower TER
Caveat: Deeper drawdown · Lower trailing returns
Canara Robeco Mid Cap Fund
Canara Robeco Mutual Fund
- 1Y
- -2.4%
- 3Y
- +15.4%
- Vol
- 15.1%
- Max DD
- -21.2%
- Sharpe
- 0.71
- 3Y win
- 0%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
HSBC Midcap Fund
HSBC Mutual Fund
- 1Y
- +9.6%
- 3Y
- +21.6%
- Vol
- 17.2%
- Max DD
- -26.0%
- Sharpe
- 0.91
- 3Y win
- +100%
- Higher win rate vs category
- Higher trailing returns
Caveat: Higher volatility · Deeper drawdown · Higher TER